6.1 The committee concluded that GreenLight XPS is as effective as transurethral resection of the prostate (TURP) for treating benign prostatic hyperplasia in non-high-risk patients. The committee considered that the evidence for the use of GreenLight XPS in high-risk patients is limited, but accepted expert advice that the clinical benefits of its use in this population are plausible. It concluded that further comparative clinical evidence of the benefits of GreenLight XPS in high-risk patients is needed before recommending the procedure for routine adoption in this population.
6.2 The committee considered that the evidence for GreenLight XPS allowing more procedures to be done on a day-case basis than current practice was both convincing and compelling. The committee concluded that adopting the GreenLight XPS system is likely to drive an increase in rates of day-case surgery and that planning for the redesign of urological services would be required to accommodate this.
6.3 The committee concluded that, in non-high-risk patients, adopting the GreenLight XPS system is likely to be cost saving compared with TURP, only if the current arrangement where consoles are provided at no cost to the hospital based on a contracted commitment to fibre usage is continued (see section 5.20), and that high rates of day-case treatment are achieved.
Chair, medical technologies advisory committee